JP2024520690A5 - - Google Patents

Info

Publication number
JP2024520690A5
JP2024520690A5 JP2023574531A JP2023574531A JP2024520690A5 JP 2024520690 A5 JP2024520690 A5 JP 2024520690A5 JP 2023574531 A JP2023574531 A JP 2023574531A JP 2023574531 A JP2023574531 A JP 2023574531A JP 2024520690 A5 JP2024520690 A5 JP 2024520690A5
Authority
JP
Japan
Prior art keywords
composition
use according
nitroxoline
pharmaceutically acceptable
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520690A (ja
Filing date
Publication date
Priority claimed from GBGB2108224.3A external-priority patent/GB202108224D0/en
Application filed filed Critical
Publication of JP2024520690A publication Critical patent/JP2024520690A/ja
Publication of JP2024520690A5 publication Critical patent/JP2024520690A5/ja
Pending legal-status Critical Current

Links

JP2023574531A 2021-06-09 2022-06-09 皮膚神経線維腫の治療に使用するためのニトロキソリン Pending JP2024520690A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2108224.3 2021-06-09
GBGB2108224.3A GB202108224D0 (en) 2021-06-09 2021-06-09 Treatment
PCT/GB2022/051442 WO2022258972A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma

Publications (2)

Publication Number Publication Date
JP2024520690A JP2024520690A (ja) 2024-05-24
JP2024520690A5 true JP2024520690A5 (enExample) 2025-06-12

Family

ID=76838879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574531A Pending JP2024520690A (ja) 2021-06-09 2022-06-09 皮膚神経線維腫の治療に使用するためのニトロキソリン

Country Status (12)

Country Link
US (1) US20240261276A1 (enExample)
EP (1) EP4351576A1 (enExample)
JP (1) JP2024520690A (enExample)
KR (1) KR20240024175A (enExample)
CN (1) CN117769419A (enExample)
AU (1) AU2022290019A1 (enExample)
BR (1) BR112023025789A2 (enExample)
CA (1) CA3221964A1 (enExample)
GB (1) GB202108224D0 (enExample)
IL (1) IL309177A (enExample)
MX (1) MX2023014530A (enExample)
WO (1) WO2022258972A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202116743D0 (en) * 2021-11-19 2022-01-05 Healx Ltd Treatment
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970128B1 (en) * 2013-03-15 2019-12-04 Asieris Pharmaceutical Technologies Co., Ltd. Base addition salts of nitroxoline and uses thereof
CA3287905A1 (en) * 2016-10-14 2025-11-29 Wake Forest University Health Sciences Compositions, cell constructs, and methods of making and using the same
EP3883552B1 (en) * 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
CN112402388A (zh) * 2019-08-05 2021-02-26 江苏亚虹医药科技股份有限公司 一种用于治疗膀胱癌的口服固体制剂及其制备方法

Similar Documents

Publication Publication Date Title
JP2023041862A5 (enExample)
JP2023541430A5 (enExample)
JP2023515472A5 (enExample)
JP2014515373A5 (enExample)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
RU2010147287A (ru) Комбинированная композиция
JP2024516795A5 (enExample)
JP2024534427A5 (enExample)
JP2024540439A5 (enExample)
AU2009215329B2 (en) Combination comprising paclitaxel for treating ovarian cancer
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2023522415A5 (enExample)
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
JP2016505050A5 (enExample)
JP2025148449A5 (enExample)
JP2024531799A5 (enExample)
JP2025511402A5 (enExample)
JP2025511401A5 (enExample)
JP2025509278A5 (enExample)
JP2022177119A5 (enExample)
JP2024528731A5 (enExample)
JP2023517130A5 (ja) Azd1656又はその薬学的に許容される塩を含む、コロナウイルスによって引き起こされた肺炎及び/又は心筋炎の治療用組成物
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物
JP2022540198A (ja) 組合せ